Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Closes Feb.24?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(76)
•••
Comment by Straylighton Feb 17, 2021 7:24pm
192 Views
Post# 32591727

RE:Closes Feb.24?

RE:Closes Feb.24?It does make me wonder if there is something behind the scenes that they needed the money for quickly. They may have been planning this deal for a little while but when the $20m USD landed in their lap last week surely they could have backed out of this by now if they wanted to.

I dont know how exactly the cash flow for a phase 3 works but assuming they needed like ~$50m for it I would have thought they would be fine to hold out at least a little longer if they wanted to.

Moving ahead for testing for one of their other drugs? P3 starting sooner than expected? NASDAQ requirement in some way? Or just making sure they have enough in the bank for a strong negotiating position?

I'm not sure but I'm hoping this is good news in the long term. At the moment it leaves me scratching my head a bit and hoping (which isn't ideal in investing) that there is method behind 'the whatever this is'.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities